XTalks

AUGUST 5, 2022

ChemoCentryx made its way into news in October 2021 when it clenched its first ever US Food and Drug Administration (FDA) approval in 24 years for the drug Tavneos (avacopan) for patients with serious autoimmune disease. CCX507 is a potential treatment for inflammatory bowel disease that completed Phase I clinical development.

Development 52

Development FDA Approval Sales Drugs 52

XTalks

NOVEMBER 15, 2021

Now, new research shows that the brain hormone serotonin may cause gut inflammation that could trigger flare-ups in Crohn’s disease. Crohn’s disease is one of the two main types of inflammatory bowel disease (IBD), along with ulcerative colitis.

Hormones 98

Hormones Regulation Research Production 98

The Pharma Data

JUNE 17, 2022

Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn’s disease, ADVANCE, MOTIVATE and FORTIFY 1-4. Experience the interactive Multimedia News Release here: [link].

FDA Approval 40

FDA Approval Clinical Trials Clinical Trials Trials 40

The Pharma Data

OCTOBER 1, 2021

Deucravacitinib demonstrated efficacy no matter baseline characteristics, including weight , disease severity and former treatment with biologic or non-biologic therapies. These data (Presentation #2857) are being presented today during the Late Breaking News Session from 3:45 – 4:45 p.m. million people within the us.

Dermatology 52

Dermatology Trials Clinical Development Research 52

The Pharma Data

FEBRUARY 22, 2021

. “These positive results confirm the findings of the previous induction study and underscore the potential impact upadacitinib could have on patients struggling to manage their disease.” lead study investigator and head of the Inflammatory Bowel Diseases Centre at Humanitas Research Hospital, Milan, Italy.

Medicine 52

Medicine Development Drugs Trials 52

Pharma Times

APRIL 15, 2024

Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis

Research 144

Research 144

Pharma Times

APRIL 29, 2024

The method has the potential to be used to deliver RNA to the bloodstream for a range of diseases

RNA 107

RNA Drugs 107

The Pharma Data

JUNE 18, 2021

In the ADVANCE study, risankizumab showed efficacy regardless of prior treatment status by subgroup analysis in patients with moderate to severe Crohn’s disease, and non-bio-IR patients had numerically higher rates of efficacy compared to bio-IR patients. 1 No new safety risks were observed. NORTH CHICAGO, Ill. ,

Clinical Trials 40

Clinical Trials Clinical Trials Trials Development 40

The Pharma Data

JUNE 30, 2021

“Ulcerative colitis is a disease with unpredictable symptoms and frequent flares, which can make daily life challenging,” said Michael Severino, M.D., “Ulcerative colitis is a disease with unpredictable symptoms and frequent flares, which can make daily life challenging,” said Michael Severino, M.D.,

Medicine 52

Medicine Bacteria Vaccination Vaccine 52

The Pharma Data

JUNE 18, 2021

1 Clinical remission was defined by Crohn’s Disease Activity Index (CDAI) in the U.S. “These results represent another step towards the development of risankizumab for these patients, many of whom do not find sufficient disease control with current treatments.” 1-7 No new safety risks were observed.

Trials 40

Trials Development Clinical Trials Clinical Trials 40

XTalks

JULY 3, 2023

We are delighted with the FDA’s approval of Suflave — which has efficacy equivalent to Suprep, but with a taste similar to a sports drink,” said Alan Cooke, president and CEO of Sebela Pharmaceuticals, in the company’s news release. Around eight in ten patients indicated that they would request Suflave for their next colonoscopy.

FDA Approval 97

FDA Approval Compliance Clinical Trials Clinical Trials 97

Drug Discovery World

SEPTEMBER 28, 2022

Whilst we know that AI has been effective in practices such as validating targets that may be suitable to treat a disease, it faces a plethora of significant challenges. These areas include oncology, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease or lupus, and rare diseases such as fragile X syndrome.

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

Drug Discovery World

DECEMBER 21, 2023

Insilico Medicine has initiated the first-in-human study for ISM5411, a poly hydroxylase domain (PHD) 1/2 inhibitor for the treatment of inflammatory bowel disease (IBD) designed by its generative AI platform. Neither disorder is curable, and they both increase the risk of colorectal cancer up to four times.

Trials 52

Trials Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

DECEMBER 21, 2023

The total sales of inflammatory bowel disease (IBD) drugs are estimated to reach approximately $10.2 In 2007, AbbVie’s Humira received approval from the FDA to treat moderate-severe Crohn’s disease (CD). In 2007, AbbVie’s Humira received approval from the FDA to treat moderate-severe Crohn’s disease (CD).

Marketing 52

Marketing Sales Drugs Medicine 52

The Pharma Data

JUNE 18, 2021

Atopic dermatitis is a chronic, relapsing inflammatory condition characterized by a cycle of intense itching and scratching leading to cracked, scaly, oozing skin. 4,5 Between 20 and 46 percent of adults with atopic dermatitis have moderate to severe disease. About RINVOQ ® (upadacitinib). 14 In August 2019 , RINVOQ received U.S.

Medicine 40

Medicine Production Trials Development 40

Drug Discovery World

SEPTEMBER 22, 2023

The researchers found that in healthy guts there was a specialised subset of gamma delta T cells (V-gamma-4 (Vg4) cells) that were significantly altered and often depleted in inflammatory bowel disease (IBD) samples. This suggests that assessing the status of Vg4 T cells could be a useful biomarker for disease progression.

Gene 52

Gene Development Research Clinical Research 52

Drug Discovery World

MARCH 29, 2023

Direct Biologics uses extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs) to address multiple disease indications. ExoFlo’s safety profile, combined with its anti-inflammatory, immunomodulatory and regenerative properties, make it an ideal next generation candidate for ulcerative colitis.

Drug Trials 52

Drug Trials Trials Drugs Clinical Trials 52

pharmaphorum

JUNE 20, 2022

AbbVie’s IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn’s disease after getting approval for the new indication from the FDA. The post AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval appeared first on.

Sales 62

Sales Trials Branding Drugs 62

Drug Discovery World

JANUARY 4, 2023

Celltrion USA has submitted a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act for CT-P13 SC for the treatment of inflammatory bowel disease (IBD). To read this content in full, you need to login.

Licensing 52

Licensing Licensing Drugs Trials 52

pharmaphorum

MAY 12, 2022

AbbVie’s would-be blockbuster Rinvoq has notched up another positive trial in Crohn’s disease, showing that it can achieve clinical remission over a full year when used as a maintenance therapy. ” For AbbVie, the results could unlock sales of $1.3

Trials 62

Trials Sales Drugs 62

pharmaphorum

MAY 25, 2022

Yesterday, the company reported the results of the two trials of the S1P receptor modulator in patients with moderately-to-severely active UC at the Digestive Disease Week congress, with the data suggesting it could mount a strong challenge against rival Zeposia (ozanimod) from Bristol-Myers Squibb. Pfizer placed a $6.7

Trials 57

Trials Sales Drugs Production 57

pharmaphorum

MAY 24, 2022

The results of the LUCENT-2 trial presented today at Digestive Disease Week (DDW) meeting found that among patients with UC who responded to the drug at 12 weeks, 49.9% In addition, 40% of mirikizumab patients achieved resolution or near resolution of bowel urgency, considered to be one of the most distressing symptoms of UC, said Lilly.

Trials 57

Trials Antibody Marketing Sales 57

pharmaphorum

FEBRUARY 21, 2022

Symptoms such as stool frequency, bowel urgency and bleeding were abolished in 46% of the mirikizumab group and 28% of the control group, and 22% of those taking Lilly’s antibody saw an impact on symptoms within four weeks of starting the drug.

Antibody 57

Antibody Trials Drugs Marketing 57

pharmaphorum

SEPTEMBER 12, 2020

The non-profit US watchdog is carrying out a review of eight targeted immune modulator (TIM) drugs used to treat inflammatory bowel disease (IBD) and says that all provide significant health benefits. However, they are simply too expensive, even after rebates, according to ICER’s calculations.

Drugs 52

Drugs Sales Marketing 52

pharmaphorum

AUGUST 10, 2020

The Swiss drugmaker has acknowledged that the dual-acting anti-integrin antibody – which is trying to chase down Takeda’s blockbuster Entyvio in UC – generated “disappointing” results from the programme, which is billed as the largest ever undertaken in inflammatory bowel disease (IBD).

Drugs 52

Drugs Antibody Trials Sales 52

XTalks

OCTOBER 6, 2020

Mammen added that, “For more than 20 years, we at Janssen have been committed to researching anti-TNF biologic agents for immune-mediated diseases and are encouraged to expand treatment options for these patients.”. There are six different TNF inhibitors that are FDA approved for the treatment of rheumatic diseases.

FDA Approval 71

FDA Approval Clinical Trials Clinical Trials Trials 71

Delveinsight

JULY 27, 2021

Cassava Sciences , based in Austin, Texas, a clinical stage biopharmaceutical company dealing with neuroscience stated constructive results of an investigational diagnostic/biomarker to mark Alzheimer’s disease (AD) with a blood test. The company’s total gain from previous year was wiped out completely.

Vaccination 96

Vaccination Vaccine Trials Manufacturing 96

The Pharma Data

MAY 15, 2021

And it was all because of my occasional constipation problem … Sometimes going weeks without a bowel movement is the “constipation hell” I had been living with. Well, finally, there is great news for you … Hanako told me about the 6 ancient Japanese nutrients that can end occasional constipation.

Production 52

Production Packaging Packaging Bacteria 52

The Pharma Data

MAY 15, 2021

Product Name: End of Gout cb vsl | Blue Heron Health News. Click here to get End of Gout cb vsl | Blue Heron Health News at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. But there’s a serious problem here.

Bacteria 52

Bacteria Doctors Doctor Production 52

pharmaphorum

OCTOBER 7, 2021

Bristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) have been hit by a mid-stage failure in ulcerative colitis.

Trials 57

Trials Sales Drugs Marketing 57

Pharmaceutical Technology

DECEMBER 4, 2022

Biosimilars have slightly different structures than the originator biologics but have the same effect in treating a disease. Humira is indicated for 10 adult and pediatric conditions, including Crohn’s disease, rheumatoid arthritis, and ulcerative colitis, as per its label. but] for biosimilars, it is all about the money.

Marketing 262

Marketing Pharmacy Production Branding 262